The global shingles vaccine market size accounted for USD 4.94 billion in 2024, grew to USD 5.69 billion in 2025 and is expected to be worth around USD 20.57 billion by 2034, registering a healthy CAGR of 15.34% between 2024 and 2034. The North America shingles vaccine market size is evaluated at USD 3.11 billion in 2024 and is expected to grow at a notable CAGR of 15.41% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Shingles Vaccine Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Shingles Vaccine Market Revenue and Volume, By Product, 2024-2034
8.1.1 Shingrix
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Zostavax
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. SkyZoster
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Shingles Vaccine Market Revenue and Volume, By Vaccine Type, 2024-2034
9.1.1. Recombinant Vaccine
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Live Attenuated Vaccine
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.1.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.5.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2021-2034)
11.1. GlaxoSmithKline plc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Merck & Co., Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CanSinoBIO
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Vaccitech
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Green Cross Corp
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Genuine Life Science
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. SK Bioscience
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample